Ticker
AKBA

Price
0.40
Stock movement up
+0.01 (2.56%)
Company name
Akebia Ther
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsverdi
73.41M
Ent verdi
408.09M
Pris/omsetning
0.33
Pris/bok
2.81
Utbytte avkastning
-
Utbytte vekst
-
Vekst år
-
FCF-utbetaling
-
Etterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års avkastning
-85.07%
3 års avkastning
-54.30%
5 års avkastning
-51.63%
10 års avkastning
-
Sist oppdatert: 2022-08-25

UTBYTTE

AKBA betaler ikke utbytte

VERDSETTELSE

Verdsettelsesforhold

Loading...
Verdsettelsesforhold-data
Etterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Verdsettelse (Salg/Bokført verdi)

Loading...
Verdsettelse (Salg/Bokført verdi) data
Pris til omsetning0.33
Pris til bok2.81
EV i forhold til salg1.83

ØKONOMI

Per aksje

Loading...
Per aksje-data
Gjeldende aksje antall183.53M
EPS (TTM)-1.57
FCF per aksje (TTM)-1.16

Resultatregnskap

Loading...
Resultatregnskap-data
Inntekter (TTM)222.97M
Bruttofortjeneste (TTM)72.84M
Driftsinntekter (TTM)-258.88M
Netto inntekt (TTM)-275.68M
EPS (TTM)-1.57
EPS (1 år fremover)-0.44

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)32.67%
Driftsmargin (TTM)-116.10%
Fortjenestemargin (TTM)-123.64%

Balanse

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
Kontanter174.56M
Netto fordringer64.58M
Samlede omløpsmidler302.69M
Goodwill55.05M
Immaterielle eiendeler99.12M
Eiendom, anlegg og utstyr0.00
Sum eiendeler535.36M
Leverandørgjeld19.47M
Kortsiktig/nåværende langsiktig gjeld135.19M
Sum kortsiktig gjeld253.91M
Sum gjeld509.24M
Aksjonærenes egenkapital26.12M
Netto varige driftsmidler-128.05M

Kontantstrøm

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
Kontantstrøm fra drift (TTM)-203.84M
Kapitalutgifter (TTM)0.00
Fri kontantstrøm (TTM)-203.84M
Utbetalt utbytte (TTM)0.00

Finansielle inntekter

Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
Egenkapitalavkastning-1055.60%
Avkastning på eiendeler-51.49%
Avkastning på investert kapital-222.39%
Kontantavkastning på investert kapital-164.43%

AKSJEINFORMASJON

Aksjediagram

Loading...
Aksjekurs-data
Åpning0.39
Daglig høy0.41
Daglig lav0.39
Daglig volum2.04M
Tidenes høyeste29.17
1 år analytikerestimat1.63
Beta1.47
EPS (TTM)-1.57
Utbytte per aksje-
Ex-div dato-
Neste dato for resultatpresentasjon2 Nov 2022

Nedsidepotensial

Loading...
Nedsidepotensial-data
AKBAS&P500
Nåværende prisfall fra toppnotering-98.63%-12.18%
Høyeste prisfall-98.91%-56.47%
Dato for høyeste fall24 May 20229 Mar 2009
Gj.snittlig fall fra topp-69.43%-11.38%
Gj.snittlig tid til ny topp354 days12 days
Maks tid til ny topp2061 days1805 days
SELSKAPSOPPLYSNINGER
AKBA (Akebia Ther) company logo
Markedsverdi
73.41M
Markedsverdi kategori
Small-cap
Beskrivelse
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Ansatte
426
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
John P. Butler
Land
USA
By
Cambridge
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted six newly-hired employees options to purchase a...
2. september 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
1. september 2022
Akebia Therapeutics Inc (NASDAQ: AKBA) announced initial findings from an investigator-sponsored study evaluating vadadustat for Acute Respiratory Distress Syndrome (ARDS) with COVID-19 and hypoxemia....
5. august 2022
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 174.19% and 158.19%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
4. august 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarte...
4. august 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced initial findings from an investigator-...
4. august 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results ...
26. juli 2022
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to t...
30. juni 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
3. juni 2022
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Offic...
19. mai 2022
Neste side